MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of marketable...
$241,756K
Proceeds from exercise of
stock options
$43K
Net cash provided by
(used in) investing...
$158,400K
Net cash provided by
financing activities
$43K
Canceled cashflow
$83,356K
Net increase
(decrease) in cash, cash...
$43,366K
Canceled cashflow
$115,077K
Purchases of marketable
securities
$81,687K
Purchase of in-process
research and development
$1,188K
Purchase of property and
equipment
$481K
Stock-based compensation
expense
$12,134K
Accrued restructuring
costs
$10,646K
Impairment of long-lived
assets
$10,197K
Accounts payable
$6,533K
Other non-current
assets
-$5,311K
Amortization of operating
lease right-of-use...
$1,080K
Depreciation
$712K
Acquired in-process
research and development
$665K
Prepaid expenses and
other current assets
-$316K
Net cash used in
operating activities
-$115,077K
Canceled cashflow
$47,594K
something is missing
-$134,435K
Accrued clinical and
research and development...
-$11,721K
Accrued expenses and
other current...
-$8,590K
Operating lease
liabilities
-$6,447K
Accretion on investments
in marketable...
$1,478K
Back
Back
Cash Flow
source: myfinsight.com
CARGO Therapeutics, Inc. (CRGX)
CARGO Therapeutics, Inc. (CRGX)